Medivation and Astellas Announce Enzalutamide Data

Medivation MDVN and Astellas Pharma announced data for enzalutamide (formerly MDV3100), an investigational, oral, androgen receptor signaling inhibitor, relating to the secondary endpoints of health-related quality of life and time to first skeletal-related event in men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. These new data from the Phase 3 AFFIRM study were presented today at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago, IL by Johann de Bono, MBChB, FRCP, MSc, PhD, of The Institute of Cancer Research and Royal Marsden Hospital, London, and co-principal investigator of the AFFIRM trial. "In this study, enzalutamide demonstrated an improvement in quality of life measures and time to first skeletal-related event," said Professor de Bono. "The success of this trial could give doctors a new therapy option for men with advanced prostate cancer."